Seventh Framework Programme - European Union
An EU consortium to identify novel targets and drugs for cancer treatment

Buzz Baum


Laboratory for Molecular Cell Biology, University College, London London, UK

Buzz and his research team are exploring how changes in cell shape and dynamics can contribute to cancer. Together with other members of the CancerPathways research network he has helped pioneer new large-scale GM technologies such as RNAi in flies to hunt for cancer-risk genes. This is key to uncovering new therapeutic targets and improving our understanding of how cancer develops.

His team has created a database called FLIGHT to facilitate the analysis, integration and dissemination of data from RNAi screens. The lab was recently awarded two major cancer grants from the Association of International Cancer Research and Cancer Research UK to use RNAi to search for new cancer-relevant genes that play a role in the formation of the cytoskeleton.

University College London (UCL) is one of the largest universities in the UK. With 27,000 staff and students and 19 Nobel prizes under its belt, the University is widely recognized for excellence in teaching and research. The UCL’s Laboratory for Molecular Cell Biology (LMCB) constitutes the primary Medical Research Council (MRC) funded cell biology institute in the UK. Together with the MRC Cell Biology Unit (CBU) some 130 scientists carry out research relevant to many human diseases including cancer.